CAMBRIDGE, Mass., Oct. 21,
2022 /PRNewswire/ -- Akebia Therapeutics, Inc.
(Nasdaq: AKBA), a biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease, today
announced that it will present data at the American Society of
Nephrology Kidney Week 2022 (ASN Kidney Week 2022), which will take
place in Orlando, November 3-6, 2022.
The poster titled, "Prevalence of Hyporesponse to
Erythropoiesis-Stimulating Agents Among Medicare Patients with
CKD-Related Anemia According to Absolute or Weight-Based
Definitions," poster number TH-PO666, will be presented during the
Anemia and Iron Metabolism session on Thursday, November 3 from 10:00 a.m. to 12:00 p.m. EDT. View the abstract
ASN Kidney Week 2022 attendees can visit the Akebia Booth #1721.
About Akebia Therapeutics
Inc. is a fully integrated biopharmaceutical company with the
purpose to better the lives of people impacted by kidney disease.
Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
View original content to download
SOURCE Akebia Therapeutics